Efficacy and Safety of Sodium Glucose Cotransporter 2 Inhibitor in Heart Transplant Recipients with Chronic Kidney Disease [0.03%]
钠-葡萄糖协同转运蛋白2抑制剂在慢性肾脏病心脏移植受者中的疗效和安全性
Satoru Ando,Masaki Tsuji,Shun Kitamura et al.
Satoru Ando et al.
Chronic kidney disease (CKD) is a major long-term complication following heart transplantation (HT). The safety and efficacy of sodium-glucose cotransporter 2 inhibitors (SGLT2i) for HT recipients with CKD remains unclear. We retrospectivel...
Pseudo-Hypertrophy [0.03%]
假性肥大
Kenichi Inoue,Takumi Hatta,Ryuta Watanabe et al.
Kenichi Inoue et al.
Covered Stent Treatment of a Left Circumflex Posterolateral Branch Aneurysm [0.03%]
左回旋支后侧枝动脉瘤的覆膜支架治疗
Tetsuro Nagao,Riku Arai,Koichiro Hori et al.
Tetsuro Nagao et al.
SGLT2 Inhibitor Use and Outcomes in Patients with Acute Heart Failure and Low Body Mass Index [0.03%]
急性心力衰竭伴低体质指数患者使用钠-葡萄糖协同转运蛋白2抑制剂及其疗效
Yusuke Uemura,Toru Kondo,Yuta Ozaki et al.
Yusuke Uemura et al.
Sodium-glucose cotransporter 2 inhibitors (SGLT2is) improve clinical outcomes in patients with heart failure (HF) with a broad range of body mass indices (BMIs); however, concerns remain regarding their tolerability, safety, and clinical ou...
A Giant Saccular Cavo-Tricuspid Isthmus Pouch in a Patient with Common Atrial Flutter [0.03%]
一名患有心房 flutter 的患者出现巨大型腔室三尖瓣 isthmus 囊肿
Daisuke Yoshida,Masao Takemoto,Eiji Nyuta et al.
Daisuke Yoshida et al.
Efficacy of 15 mg Edoxaban on Long-Term Outcome after Percutaneous Coronary Intervention in Patients with Atrial Fibrillation and High Bleeding Risk [0.03%]
用于高出血风险的心房颤动患者的经皮冠状动脉介入术长期疗效的艾多沙班剂量探索研究：EDOXIAN PCI研究
Takao Sato,Yoshifusa Aizawa,Toshihiro Miyamoto et al.
Takao Sato et al.
In patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI), dual antiplatelet therapy (DAPT) plus oral anticoagulants increase bleeding risk. Low-dose edoxaban (15 mg) is safe for high-risk older patients ...
Errata: Dampened Reactive Hematopoiesis and Systemic Inflammatory Response Following Early Recurrent Myocardial Infarction in Mice [0.03%]
小鼠早期复发性心肌梗死后造血功能抑制和全身炎症反应的矫正 Erratum
Several errors (shown with underlines) in the following list appeared in the article "Dampened Reactive Hematopoiesis and Systemic Inflammatory Response Following Early Recurrent Myocardial Infarction in Mice" by Yunhang Zhang, Haiju He, an...
Severe Coronary Vasospasm with Extensive Myocardial Necrosis and Refractory Ventricular Fibrillation [0.03%]
严重冠状动脉痉挛伴大面积心肌梗死和难治性室颤
Tetsuro Nagao,Riku Arai,Koichiro Hori et al.
Tetsuro Nagao et al.
Effective Transcatheter Mitral Valve Repair for Reverse Remodeling in Cancer Therapy-Related Cardiac Dysfunction [0.03%]
经导管有效二尖瓣修复在癌症治疗相关心脏功能障碍中的逆向重构作用
Naoko Kawabata,Naka Sakamoto,Kenta Iyobe et al.
Naoko Kawabata et al.
Cancer therapy-related cardiac dysfunction (CTRCD) is an emerging disease. As there is no specific treatment for CTRCD, the standard therapy for cardiac failure is typically administered. In patients with heart failure and severe secondary ...
Case Reports
International heart journal. 2026;67(3):280-285. DOI:10.1536/ihj.25-649 2026
TIF1β Promotes Myocardial Ischemia-Reperfusion Injury by Stabilizing TRAF6 through Mediating TRAF6 SUMOylation [0.03%]
TIF1β通过介导TRAF6的SUMO化来稳定TRAF6，从而促进心肌缺血再灌注损伤
Yue Nan,Xu Zhang,Xinping Du et al.
Yue Nan et al.
Myocardial ischemia-reperfusion injury (MIRI) exacerbates myocardial damage, resulting in a further decline in heart function. Abnormally high TRAF6 expression was reported in MIRI. However, what actually causes the abnormally elevated expr...